Reading Time: 7 minutesMND research has exploded over the last decade and we know more about the disease now than ever before. However, there are still many things
Author: Kiran Goyal
I work as a Research Officer within the MND Association to help organise the International Symposium and communicating the latest updates of MND research across our social media platforms. I graduated with a master's degree in Neuroscience from Cardiff University in 2023. I have previously supported the awareness of Fragile X syndrome within the UK.
Reading Time: 10 minutesFor the purposes of this blog, ALS should be taken to mean ALS/MND. In September 2020 we published a blog article discussing Dr Rick Bedlack’s
Reading Time: 6 minutesWeight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 7 minutesWeight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 5 minutesWeight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 5 minutesWeight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 6 minutesWeight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 5 minutesHi, I’m Ben, a researcher working at Sheffield University. I attended last year’s International Symposium on ALS/MND as one of the Symposium Communication Ambassadors and
Reading Time: 7 minutesHi, I’m Heather, a PhD student from King’s College London, and a Communications Ambassador for the 34th International Symposium on ALS/MND which was held in Basel last December. Over 1,300 attendees from around the world gathered to connect with researchers and people affected by MND and engage with the latest research presented in the platform presentation and poster sessions. In this blog post, I will be sharing several of my personal highlights of the symposium, which cover how differences in our genetic code can be explored to understand their effects on MND risk and progression.
Reading Time: 5 minutes"New drug reduces risk of death by 50%"
You may have seen this type of headline in news articles reporting on the outcome of clinical trials. Reading this headline can lead people to believe a potential drug is highly beneficial and has a real impact. However, it is important to delve a little deeper into the meaning of ‘risk of death’, the raw data behind it, and how it should be considered alongside other outcome measures of a trial to fully determine how effective a drug might be.